
Loading, please wait...

Loading, please wait...

Noise exposure (NE) represents a major cause of sensorineural hearing loss. It primarily disrupts the Blood-Labyrinth Barrier Repair processes by damaging the stria vascularis. Recent studies highlight that this trauma specifically affects perivascular macrophage-like melanocytes (PVM/Ms) and critical cell junctions. This damage leads to a significant loss of hair cells and hearing sensitivity. Understanding these vascular changes is vital for developing effective clinical interventions in audiology.
Proteomic research using iTRAQ and PRM identified nine altered proteins in the stria vascularis. These proteins belong to functional modules like junctional stability and immune modulation. Furthermore, PPI-GO analysis linked these proteins to the regulation of cell junction assembly. Consequently, researchers identified a key axis involving PVM/Ms and VEGF/PEDF signaling. This axis coordinates the time-dependent recovery of the cochlear microvasculature.
Studies show an acute reduction in PVM/Ms coverage immediately following noise trauma. Simultaneously, levels of VEGF, PEDF, and various junctional proteins drop significantly. However, a coordinated repair process begins soon after the initial insult. Specifically, VEGF and VEGFR2 peak at two days post-exposure. Following this, PEDF and VEGFR1 reach their maximum levels at seven days. This sequence facilitates the restoration of VE-Cadherin and ZO-1 while inducing a compensatory rise in Occludin levels.
Ultimately, the stria vascularis undergoes a structured response to injury. The interplay between pro-angiogenic and anti-angiogenic factors ensures long-term barrier stability. Therefore, targeting the PVM/Ms-VEGF/PEDF axis may offer a novel therapeutic window for treating noise-induced hearing loss. Clinicians should monitor these vascular markers to better understand the recovery potential of the inner ear.
Noise exposure causes mechanical and metabolic stress that breaks down the blood-labyrinth barrier. This process involves the loss of protective PVM/Ms and the degradation of tight junction proteins like ZO-1 and Occludin, which are essential for fluid homeostasis.
VEGF acts as an early responder in the repair process. Its levels peak within 48 hours of noise exposure to promote vascular stability and initiate the assembly of cell junctions, which are crucial for restoring barrier integrity.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A proteomic study reveals how the VEGF/PEDF signaling axis and PVM/Ms coordinate to repair the blood-labyrinth barrier after noise-induced hearing loss....
7 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today